Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673938 | 0.91 | LOXL2 (0.33) | AKR1B1 | |
| SCHEMBL4672028 | 0.90 | AKR1B1 (0.34) | AKR1B1KMT2A | |
| SCHEMBL4676313 | 0.84 | AKR1B1 (0.34) | HTR2AKCNH2AKR1B1MEN1KMT2A | |
| SCHEMBL4677355 | 0.82 | HTR2A (0.31) | HTR2AKCNH2AKR1B1 | |
| SCHEMBL4674789 | 0.80 | MAPT (0.35) | HTR2AKCNH2AKR1B1MEN1KMT2A | |
| SCHEMBL4674438 | 0.80 | HTR2A (0.31) | HTR2AKCNH2AKR1B1 | |
| SCHEMBL4674048 | 0.79 | AKR1B1 (0.41) | HTR2AKCNH2AKR1B1 | |
| SCHEMBL4676696 | 0.79 | HTR2A (0.39) | HTR2AKCNH2AKR1B1PTGS2MEN1 | |
| SCHEMBL4676699 | 0.79 | HTR2A (0.39) | HTR2AKCNH2AKR1B1PTGS2MEN1 | |
| SCHEMBL4672331 | 0.78 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142872-B1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | HTR2A 441/4885KCNH2 3174/4885AKR1B1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.